 Alligator Bioscience Nasdaq Stockholm: ATORX and Scandion Oncology Spotlight, Sweden: SCOL, today announced signing of a collaboration agreement. The two companies have agreed to explore the anti-tumor efficacy of the CD40 antibody mitazalimab Alligator Bioscience in combination with SCO-101 Scandion Oncology as an addition to chemotherapy in resistant preclinical tumor models. The expectation is that SCO-101 will revert chemotherapy resistance and thereby further strengthening the anti-tumor effects of mitazalimab. 